Every material Form 8-K Omega Healthcare Investors filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Omega Healthcare Investors reported third-quarter 2025 net income of $185 million, or $0.59 per diluted share, up from $115 million, or $0.42, a year earlier. The company raised its 2025 AFFO guidance to $3.08-$3.10 per diluted share from $3.04-$3.07, which affects shareholders' expectations for cash earnings from the year's investments.
Q3 2025 net income of $185 million ($0.59 per diluted share) vs. $115 million ($0.42) in Q3 2024
Q3 2025 AFFO of $243 million ($0.79 per diluted share) vs. $203 million ($0.74) in Q3 2024
2025 AFFO guidance raised to $3.08-$3.10 per diluted share from $3.04-$3.07
Quarterly dividend of $0.67 per share declared October 24, 2025, payable November 17, 2025
On September 30, 2025, Omega Healthcare Investors entered a new $2.3 billion senior unsecured credit facility, made up of a $2.0 billion revolver and a $300.0 million delayed draw term loan, and terminated its $1.45 billion 2021 revolving credit facility. The company also amended its $428.5 million term loan to reduce interest rate margins, and it had no borrowings outstanding under the new facility as of September 30, 2025.
New $2.0 billion revolving credit facility matures September 28, 2029; $300.0 million delayed draw term loan matures September 29, 2028.
Replaces the $1.45 billion 2021 revolving credit facility, which was scheduled to expire on October 30, 2025.
Term loan amendment cut interest rate margins by 35 basis points and removed the 0.100% step-up in extension periods.
Facility includes an accordion feature allowing total borrowing capacity of up to $3.0 billion; no borrowings were outstanding under the new facility as of September 30, 2025.
Omega Healthcare Investors reported second-quarter 2025 net income of $140 million and adjusted funds from operations (AFFO) of $232 million, both up from a year earlier, and raised its full-year 2025 AFFO guidance to $3.04 to $3.07 per share from $2.95 to $3.01. The company also disclosed that tenant Genesis Healthcare filed for Chapter 11 bankruptcy on July 9, 2025, and said it expects to keep receiving full rent from Genesis during the process.
Q2 2025 AFFO was $232 million, or $0.77 per share, versus $185 million, or $0.71 per share, in Q2 2024.
Q2 2025 net income was $140 million, or $0.46 per share, versus $117 million, or $0.45 per share, a year earlier.
Full-year 2025 AFFO guidance was raised to $3.04 to $3.07 per diluted share from $2.95 to $3.01.
Genesis filed for Chapter 11 on July 9, 2025; Omega agreed to provide an $8.0 million debtor-in-possession financing.
Omega Healthcare Investors completed an underwritten public offering of $600 million in 5.200% Senior Notes due July 1, 2030, under an indenture dated June 20, 2025. The company expects to use net proceeds for general corporate purposes, including possible debt repayment and healthcare real estate acquisitions, which adds long-term debt that holders of common stock will bear.
Notes priced at 99.118% of principal amount, with interest of 5.200% paid semi-annually
Notes mature July 1, 2030, with first interest payment due January 1, 2026
Notes are unsecured senior obligations, guaranteed by subsidiary OHI Healthcare Properties Limited Partnership
Offering was made under an automatic shelf registration statement on Form S-3 (Registration No. 333-282376)
Omega Healthcare Investors reported first quarter 2025 results, with revenues of $276.8 million and net income of $112.1 million, up from $69.3 million a year earlier. The REIT raised its full-year 2025 Adjusted FFO per share guidance to $2.95-$3.01 from $2.90-$2.98, but Genesis missed its March rent payment and Omega drew on a letter of credit to cover the shortfall.
Q1 2025 revenues $276.8 million, up from $243.3 million in Q1 2024; diluted EPS $0.33 versus $0.27
Q1 2025 Adjusted FFO $221 million, or $0.75 per share, versus $0.68 per share in Q1 2024
2025 Adjusted FFO guidance raised to $2.95-$3.01 per share from $2.90-$2.98
Genesis failed to pay $4.2 million of March rent; it paid full contractual rent in April 2025
Omega Healthcare Investors reported fourth-quarter and full-year 2024 results, with Q4 net income of $116 million, or $0.41 per share, up from $57 million, or $0.22 per share, a year earlier. The company also issued 2025 Adjusted FFO guidance of $2.90 to $2.98 per diluted share, which gives shareholders a reference point for the year ahead.
Q4 2024 net income was $116 million, or $0.41 per share, versus $57 million, or $0.22 per share, in Q4 2023.
Q4 2024 Adjusted FFO was $214 million, or $0.74 per share, versus $173 million, or $0.68 per share, in Q4 2023.
Q4 2024 total revenues were $279.3 million, a $40.0 million increase over Q4 2023.
The board declared a $0.67 quarterly dividend on January 29, 2025, payable February 18, 2025, to holders of record on February 10, 2025.
Omega Healthcare Investors appointed Matthew Gourmand as President and Vikas Gupta as Chief Investment Officer, effective January 1, 2025. The chief operating officer, Daniel J. Booth, is leaving after 23 years, with his employment ending January 2, 2025, and he will consult for the company through January 1, 2026.
Matthew Gourmand, previously SVP of Corporate Strategy & Investor Relations, appointed President effective January 1, 2025
Vikas Gupta, previously SVP of Acquisitions & Development, appointed Chief Investment Officer effective January 1, 2025
Dan Booth's employment ends January 2, 2025; he receives $10,000 per month in consulting fees from January 3, 2025 through January 1, 2026
New employment agreements run through December 31, 2027, with base salaries of $550,000 for Gourmand and $525,000 for Gupta
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Omega Healthcare Investors filing is on SEC EDGAR ↗. 8-K briefs of other companies →